Latest & greatest articles for metoprolol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on metoprolol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on metoprolol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for metoprolol

21. Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy.

Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. 2337713 1990 06 18 1990 06 18 2013 11 21 0959-8138 300 6729 1990 Apr 07 BMJ (Clinical research ed.) BMJ Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. 904-7 To assess whether angiotensin converting enzyme inhibition reduces proteinuria in diabetic nephropathy more than blood pressure reduction with other antihypertensive treatment. Prospective, open randomised study (...) lasting eight weeks in patients with diabetic nephropathy. Outpatient nephrology clinics. 40 Patients with type I diabetes and diabetic nephropathy with reduced renal function. Antihypertensive treatment with enalapril or metoprolol, usually combined with frusemide. Arterial blood pressure and urinary excretion of albumin and protein. Arterial blood pressure after eight weeks was 135/82 (SD 13/7) mm Hg in the group given enalapril and 136/86 (16/12) mm Hg in the group given metoprolol. Proteinuria

BMJ1990 Full Text: Link to full Text with Trip Pro

22. Noradrenergic activity and silent ischaemia in hypertensive patients with stable angina: effect of metoprolol.

Noradrenergic activity and silent ischaemia in hypertensive patients with stable angina: effect of metoprolol. 2563787 1989 03 30 1989 03 30 2015 06 16 0140-6736 1 8635 1989 Feb 25 Lancet (London, England) Lancet Noradrenergic activity and silent ischaemia in hypertensive patients with stable angina: effect of metoprolol. 403-6 30 patients (10 normotensive, 20 hypertensive) with stable angina and positive treadmill exercise tests entered a double-blind, placebo-controlled crossover trial (...) of metoprolol, 100 mg twice daily. At the end of each treatment phase, blood pressure was monitored for 24 h and Holter and real-time electrocardiographic (ECG) monitoring were carried out and an activity diary kept for 48 h. Blood samples for catecholamine measurement were taken after 30 min supine, 60 min standing, and at the first silent ischaemic event, triggered by the real-time ECG monitor, by means of an ambulatory blood withdrawal pump. Metoprolol lowered blood pressure and heart rate in both

Lancet1989

23. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.

Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. 2500169 1989 08 09 1989 08 09 2013 11 21 0959-8138 298 6681 1989 Apr 29 BMJ (Clinical research ed.) BMJ Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. 1152-7 To compare the effects (...) of metoprolol and atenolol on carbohydrate and lipid metabolism and on insulin response to an intravenous glucose load. Randomised, double blind, double dummy, controlled crossover trial. University Hospital, Uppsala, Sweden. 60 Patients with primary hypertension (diastolic blood pressure when resting supine 95-119 mm Hg on at least two occasions during four to six weeks of treatment with placebo) randomised to receive either metoprolol (n = 30) or atenolol (n = 30) during the first treatment period

BMJ1989 Full Text: Link to full Text with Trip Pro

24. Adjuvant xamoterol or metoprolol in patients with malignant ventricular arrhythmia resistant to amiodarone.

Adjuvant xamoterol or metoprolol in patients with malignant ventricular arrhythmia resistant to amiodarone. 2569105 1989 09 01 1989 09 01 2015 06 16 0140-6736 2 8658 1989 Aug 05 Lancet (London, England) Lancet Adjuvant xamoterol or metoprolol in patients with malignant ventricular arrhythmia resistant to amiodarone. 302-5 In a randomised cross-over study, six patients with recurrent sustained ventricular tachycardia (VT) were treated with 3 regimens--amiodarone, amiodarone plus metoprolol (...) , and amiodarone plus xamoterol. All patients had poor left ventricular function and were resistant to multiple drugs. Xamoterol (a partial beta-agonist) was more effective than metoprolol as adjuvant therapy to amiodarone in the control of recurrent sustained ventricular arrhythmias and was not associated with any clinical deterioration of ventricular function. Xamoterol was also more effective than metoprolol for suppression of VT at programmed stimulation and as effective as metoprolol for suppression of VT

Lancet1989

25. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study.

Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. 3346979 1988 04 19 1988 04 19 2016 10 17 0098-7484 259 13 1988 Apr 01 JAMA JAMA Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. 1976-82 The present study of primary prevention in white men aged 40 to 64 years attempts to investigate whether a beta-blocker given as initial antihypertensive treatment would lower total mortality (...) to a greater extent than thiazide diuretics. Patients were randomized to metoprolol (n = 1609, 8110 patient-years) or a thiazide diuretic (n = 1625, 8070 patient-years). The median follow-up time was 4.2 years. The mean dose of metoprolol was 174 mg/d, and of thiazide diuretics, 46 mg/d of hydrochlorothiazide or 4.4 mg/d of bendroflumethiazide. Identical control of blood pressure was achieved using a fixed therapeutic schedule. Total mortality was significantly lower for metoprolol than for thiazide

JAMA1988

26. Treating hypertension in black compared with white non-insulin dependent diabetics: a double blind trial of verapamil and metoprolol.

Treating hypertension in black compared with white non-insulin dependent diabetics: a double blind trial of verapamil and metoprolol. 3144329 1989 02 07 1989 02 07 2013 11 21 0959-8138 297 6657 1988 Nov 05 BMJ (Clinical research ed.) BMJ Treating hypertension in black compared with white non-insulin dependent diabetics: a double blind trial of verapamil and metoprolol. 1155-9 To compare responses of blood pressure to the calcium antagonist verapamil and the beta blocker metoprolol in black (...) completed the trial. Patients given slow release verapamil 120 mg or 240 mg twice daily with placebo or metoprolol 50 mg or 100 mg twice daily with placebo. Treatment for diabetes (diet alone or with oral hypoglycaemic drugs) remained unchanged. Comparison of changes in blood pressure in the two groups taking both drugs. Metoprolol had little effect on blood pressure in black patients (mean fall 4.0 mm Hg systolic (95% confidence interval -2.5 to 10.4 mm Hg), 4.3 mm Hg diastolic (-0.8 to 9.5)) but more

BMJ1988 Full Text: Link to full Text with Trip Pro

27. Economic consequences of postinfarction prophylaxis with beta blockers: cost effectiveness of metoprolol

Economic consequences of postinfarction prophylaxis with beta blockers: cost effectiveness of metoprolol Economic consequences of postinfarction prophylaxis with beta blockers: cost effectiveness of metoprolol Economic consequences of postinfarction prophylaxis with beta blockers: cost effectiveness of metoprolol Olsson G, Levin L A, Rehnqvist N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Metoprolol (Beta-blocker for postinfarction prophylaxis). Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis Study population Postinfarction patients <70 years of age. Setting The study was carried out in Sweden. Dates to which data relate Price related to 1986. Source of effectiveness data

NHS Economic Evaluation Database.1987

28. Antihypertensive treatment with metoprolol or hydrochlorothiazide in patients aged 60 to 75 years. Report from a double-blind international multicenter study.

Antihypertensive treatment with metoprolol or hydrochlorothiazide in patients aged 60 to 75 years. Report from a double-blind international multicenter study. 3511308 1986 03 26 1986 03 26 2016 10 17 0098-7484 255 10 1986 Mar 14 JAMA JAMA Antihypertensive treatment with metoprolol or hydrochlorothiazide in patients aged 60 to 75 years. Report from a double-blind international multicenter study. 1304-10 In a randomized double-blind study (N = 562), a traditional treatment schedule, starting (...) antihypertensive treatment in elderly hypertensive patients (60 to 75 years old) with 25 mg of hydrochlorothiazide once daily and doubling the dose if a satisfactory response was not achieved, was compared with antihypertensive treatment of 100 mg of metoprolol once daily, adding 12.5 mg of hydrochlorothiazide for patients whose response was not satisfactorialy achieved with metoprolol alone. Systolic and diastolic blood pressure was significantly reduced with both regimens. The frequency rates of responders

JAMA1986

29. Comparison of weight reduction with metoprolol in treatment of hypertension in young overweight patients.

Comparison of weight reduction with metoprolol in treatment of hypertension in young overweight patients. 2860441 1985 07 22 1985 07 22 2015 06 16 0140-6736 1 8440 1985 Jun 01 Lancet (London, England) Lancet Comparison of weight reduction with metoprolol in treatment of hypertension in young overweight patients. 1233-6 Weight reduction was compared with metoprolol (200 mg daily) in a randomised placebo-controlled trial of first-line treatment of mild hypertension (diastolic blood pressure 90 (...) -109 mm Hg) in 56 overweight patients aged under 55 years. After 21 weeks of follow up the weight-reduction group had lost an average of 7.4 kg. The fall in their systolic pressure of 13 mm Hg was significantly greater than that in the placebo group (7 mm Hg) but not different from that in the metoprolol group (10 mm Hg). Their fall in diastolic pressure (10 mm Hg) was greater than that in both the metoprolol (6 mm Hg) and placebo (3 mm Hg) groups. At the end of the follow-up period 50% of patients

Lancet1985

30. A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias.

A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. 6828092 1983 04 07 1983 04 07 2013 11 21 0028-4793 308 11 1983 Mar 17 The New England journal of medicine N. Engl. J. Med. A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. 614-8 During a double-blind trial in which patients with suspected myocardial infarction received metoprolol or placebo, we analyzed the occurrence (...) of ventricular tachyarrhythmias. Metoprolol (15 mg intravenously) was given as soon as possible after admission, and thereafter 200 mg was given daily for three months. Antiarrhythmic drugs were given only for ventricular fibrillation and sustained ventricular tachycardia (greater than 60 beats per second). Definite acute myocardial infarction developed in 809 of the 1395 participants, and probable infarction in 162. Metoprolol did not influence the occurrence of premature ventricular contractions or short

NEJM1983

31. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial.

Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. 6116950 1981 12 15 1981 12 15 2015 06 16 0140-6736 2 8251 1981 Oct 17 Lancet (London, England) Lancet Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. 823-7 The effect of metoprolol on mortality was compared with that of placebo in a double blind randomised trial in patients with definite or suspected acute myocardial infarction. Treatment (...) with metoprolol or placebo started as soon as possible after the patient's arrival in hospital and was continued for 90 days. Metoprolol was given as a 15 mg intravenous dose followed by oral administration of 100 mg twice daily. 1395 patients (697 on placebo and 698 on metoprolol) were included in the trial. Definite acute myocardial infarction developed in 809 and probable infarction in 162. Patients were allocated to various risk groups and within each group patients were randomly assigned to treatment

Lancet1981